| Attribute |
Value |
| 52 Week Change |
-0.38612568 |
| Address1 |
1,280 Rancho Conejo Blvd |
| All Time High |
1,639.0 |
| All Time Low |
3.92 |
| Ask |
9.54 |
| Ask Size |
1 |
| Average Analyst Rating |
1.7 - Buy |
| Average Daily Volume10 Day |
43,840 |
| Average Daily Volume3 Month |
48,977 |
| Average Volume |
48,977 |
| Average Volume10Days |
43,840 |
| Beta |
0.219 |
| Bid |
6.75 |
| Bid Size |
2 |
| Book Value |
-3.918 |
| City |
Thousand Oaks |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
9.305 |
| Current Ratio |
1.976 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
9.51 |
| Day Low |
8.8 |
| Display Name |
Atara Biotherapeutics |
| Dividend Yield |
0.0 |
| Earnings Timestamp |
1,786,564,800 |
| Earnings Timestamp End |
1,794,513,600 |
| Earnings Timestamp Start |
1,794,513,600 |
| Ebitda |
-11,058,000 |
| Ebitda Margins |
-1.78528 |
| Enterprise To Ebitda |
-8.447 |
| Enterprise To Revenue |
15.08 |
| Enterprise Value |
93,406,888 |
| Eps Current Year |
-0.95 |
| Eps Forward |
1.545 |
| Eps Trailing Twelve Months |
-1.3 |
| Esg Populated |
0 |
| Exchange |
NMS |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
9.1355 |
| Fifty Day Average Change |
0.16950035 |
| Fifty Day Average Change Percent |
0.018554032 |
| Fifty Two Week Change Percent |
-38.612568 |
| Fifty Two Week High |
19.145 |
| Fifty Two Week High Change |
-9.84 |
| Fifty Two Week High Change Percent |
-0.51397234 |
| Fifty Two Week Low |
3.92 |
| Fifty Two Week Low Change |
5.385 |
| Fifty Two Week Low Change Percent |
1.3737246 |
| Fifty Two Week Range |
3.92 - 19.145 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,413,466,200,000 |
| Float Shares |
4,623,068 |
| Forward Eps |
1.545 |
| Forward P E |
6.022654 |
| Free Cashflow |
-12,522,250 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
10 |
| Fullday Change |
-0.07499981 |
| Fullday Change Percent |
-0.7953321 |
| Fullday Price |
9.305 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.75266 |
| Gross Profits |
4,662,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.16798 |
| Held Percent Institutions |
0.5767 |
| Implied Shares Outstanding |
10,037,710 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,718,841,600 |
| Last Split Factor |
1:25 |
| Long Business Summary |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. |
| Long Name |
Atara Biotherapeutics, Inc. |
| Market |
us_market |
| Market Cap |
93,400,896 |
| Market State |
PREPRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_248196818 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-16,688,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
85,922,797 |
| Number Of Analyst Opinions |
3 |
| Open |
9.25 |
| Operating Cashflow |
-21,895,000 |
| Operating Margins |
-6.2746 |
| Payout Ratio |
0.0 |
| Phone |
805 623 4211 |
| Previous Close |
9.38 |
| Price Eps Current Year |
-9.794737 |
| Price Hint |
2 |
| Price To Book |
-2.3749363 |
| Price To Sales Trailing12 Months |
15.079253 |
| Profit Margins |
-2.69422 |
| Quick Ratio |
1.488 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
1.66667 |
| Region |
US |
| Regular Market Change |
-0.0749998 |
| Regular Market Change Percent |
-0.799572 |
| Regular Market Day High |
9.51 |
| Regular Market Day Low |
8.8 |
| Regular Market Day Range |
8.8 - 9.51 |
| Regular Market Open |
9.25 |
| Regular Market Previous Close |
9.38 |
| Regular Market Price |
9.305 |
| Regular Market Time |
1,791,921,601 |
| Regular Market Volume |
32,284 |
| Return On Assets |
-0.24139 |
| Revenue Growth |
-0.964 |
| Revenue Per Share |
0.44 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
10,037,710 |
| Shares Percent Shares Out |
0.0321 |
| Shares Short |
321,792 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
427,435 |
| Short Name |
Atara Biotherapeutics, Inc. |
| Short Percent Of Float |
0.0438 |
| Short Ratio |
6.91 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
ATRA |
| Target High Price |
18.0 |
| Target Low Price |
10.0 |
| Target Mean Price |
13.66667 |
| Target Median Price |
13.0 |
| Total Cash |
9,873,000 |
| Total Cash Per Share |
0.984 |
| Total Debt |
9,879,000 |
| Total Revenue |
6,194,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-1.3 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
8.04745 |
| Two Hundred Day Average Change |
1.2575502 |
| Two Hundred Day Average Change Percent |
0.15626693 |
| Type Disp |
Equity |
| Volume |
32,284 |
| Website |
https://www.atarabio.com |
| Zip |
91,320 |